Skip to main content
TipRanks
Go Ultimate75% OFF

Scientific Industries (SCND) AI Stock Analysis

18 Followers
SCND

Scientific Industries

(Other OTC:SCND)

Select Model
Rating:42Neutral
Price Target:$0.51â–¼(-3.96% Downside)
Action:reiterated
Date:11/14/26

SCND scores low primarily due to severe financial weakness (sharp revenue contraction, very negative margins, and significant cash burn). Technicals also reflect a clear downtrend with negative MACD and the stock trading below key moving averages, despite oversold momentum readings. Valuation is hard to support given negative earnings, while the recent leadership agreements are only a modest offset.

Positive Factors
Low Leverage and Positive EquityModest leverage and positive equity provide a balance-sheet cushion while management works through operating weakness. Limited debt burden can reduce near-term financial pressure and preserve more flexibility for restructuring, investment, or funding operations than a highly leveraged capital structure would allow.
Negative Factors
Severe Revenue ContractionThe sharp, multi-period revenue contraction indicates that the current business base is shrinking rather than merely experiencing a temporary fluctuation. A smaller revenue platform limits operating leverage, weakens reinvestment capacity, and makes a durable recovery in earnings more difficult.

Scientific Industries (SCND) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%SCND-28.76%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$6.32M
Dividend Yield
―
Average Volume (3M)
6,619
Price to Earnings (P/E)
-1.5
Beta (1Y)
0.38
Revenue Growth
-36.57%
EPS Growth
-147.82%
Country
US
Employees
55
Sector
Technology
Sector Strength
61
Industry
Hardware, Equipment & Parts

Scientific Industries Business Overview & Revenue Model

Company Description

Scientific Industries, Inc. operates as a global enterprise specializing in the development, production, and distribution of a comprehensive range of benchtop laboratory instrumentation and advanced bioprocessing systems. Their product line features...

Scientific Industries Earnings Call Summary

Earnings Call Date:Nov 15, 2024(Q3-2024)|% Change Since:-29.24%|Next Earnings Date:Nov 14, 2019
Earnings Call SentimentPositive

The earnings call highlighted significant growth in the VIVID pill counter business and successful cost-cutting initiatives, alongside promising developments and strategic partnerships in the bioprocessing segment. However, challenges in the European market remain a concern.

Positive Updates

VIVID Pill Counter Business Growth
VIVID sales in the third quarter were up 50% compared to the second quarter of this year and 12% compared to the same quarter last year. The development of a new VIVID workstation is expected to be a game-changer in the market.

Negative Updates

Challenging Bioprocessing Market
The bioprocessing segment faced a challenging environment with budget constraints impacting customers, particularly in Europe, leading to postponed equipment investments.

Company Guidance

During the third quarter of 2024, Scientific Industries demonstrated significant progress in its strategic transformation into a life sciences tool business with notable growth in sales, margins, and recurring revenue. The legacy Genie business experienced a recovery, generating positive cash flow that supports investments in the VIVID pill counter business, which saw a 50% increase in sales compared to the previous quarter and 12% year-over-year growth. The company is excited about the upcoming launch of the VIVID workstation, a new all-in-one pill counter and pharmacy management system. In the bioprocessing segment, sales increased by 12% compared to the previous year, with a remarkable 61% year-over-year growth in the U.S. market. Efforts to improve cost efficiency resulted in a reduction of operating expenses by over $1 million, or 22%, compared to the previous year. The company also reported a positive EBITDA margin of 14% for its U.S. entity in September, marking a significant milestone. Scientific Industries continues to invest in R&D and commercial activities, with a growing commercial pipeline and the successful launch of the DOTS platform, reflecting its potential to deliver long-term shareholder value.

Scientific Industries Financial Statement Overview

Summary

Overall fundamentals are very weak: TTM revenue declined sharply (-85.9%), margins are severely negative (net margin about -75%), and cash burn is heavy (TTM operating cash flow and free cash flow both deeply negative). The main offset is a relatively healthier balance sheet with low leverage (debt-to-equity ~0.14) and positive equity, but ongoing losses and cash outflows remain the dominant risk.

Income Statement

18Very Negative

Balance Sheet

54Neutral

Cash Flow

16Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Jun 2022Sep 2021
Income Statement
Total Revenue5.68M5.05M10.71M11.11M10.48M9.78M
Gross Profit1.78M1.30M4.73M5.10M4.64M4.98M
EBITDA-12.14M-7.89M-5.89M-8.51M-7.41M-4.46M
Net Income-4.27M-1.22M-6.45M-9.09M-8.15M-3.11M
Balance Sheet
Total Assets10.93M12.61M11.56M16.73M18.07M29.01M
Cash, Cash Equivalents and Short-Term Investments5.97M6.66M2.57M5.72M6.20M13.42M
Total Debt1.21M966.70K1.00M1.33M1.43M1.49M
Total Liabilities2.26M1.94M2.44M2.85M3.28M2.78M
Stockholders Equity8.67M10.66M9.12M13.89M14.79M26.22M
Cash Flow
Free Cash Flow-6.09M-8.21M-3.78M-6.29M-6.20M-3.56M
Operating Cash Flow-6.42M-8.15M-3.68M-6.16M-5.70M-3.30M
Investing Cash Flow4.10M3.83M2.87M-735.10K3.61M-10.88M
Financing Cash Flow-1001.95M645.70K5.75M2.31M16.31M

Scientific Industries Technical Analysis

Technical Analysis SentimentNegative
Last Price0.53

Price Trends

50DMA0.70Negative
100DMA0.69Negative
200DMA0.69Negative

Market Momentum

MACD-0.05Positive
RSI32.70Neutral
STOCH39.97Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCND, the sentiment is Negative. The current price of 0.53 is below the 20-day moving average (MA) of 0.62, below the 50-day MA of 0.70, and below the 200-day MA of 0.69, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 32.70 is Neutral, neither overbought nor oversold. The STOCH value of 39.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCND.

Scientific Industries Risk Analysis

Scientific Industries disclosed 12 risk factors in its most recent earnings report. Scientific Industries reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Scientific Industries Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

SCND against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$37.18B12.37-10.20%1.83%8.50%-7.62%
ELTKELTK42Neutral$39.12M-6.39-13.57%―-2.20%-297.64%
SCNDSCND42Neutral$6.32M-1.51-46.73%―-36.57%-147.82%
SVRESVRE39Underperform$335.73M-0.03-329.57%―-68.00%97.75%
SOBRSOBR38Underperform$193.94K-0.04-310.87%―17.67%92.17%

* Technology Sector Average

Performance Comparison

-50%0%SCNDELTKIMTESOBROSTSVREDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SCND and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SCNDScientific Industries 0.53-0.21-28.76%
ELTKEltek5.82-5.58-48.95%
IMTEIntegrated Media Technology0.36-0.45-55.32%
SOBRSobr Safe, Inc.0.04-2.20-98.39%
OSTOstin Technology Group Co., Ltd.1.700.000.00%
SVRESaverOne 2014 Ltd. ADR0.45-11.19-96.16%

Scientific Industries Corporate Events

Business Operations and StrategyExecutive/Board Changes

Scientific Industries Strengthens Executive Leadership Through New Agreements

Positive
Oct 2, 2026

On October 1, 2026, Scientific Industries entered into a new employment agreement with Chief Financial Officer Zachary Rovinsky, securing his role through September 30, 2028 with an annual salary of $210,000, a bonus opportunity up to 10%, and schedu...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026